For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

Gonadorelin vs Ipamorelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GonadorelinIpamorelin
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asGnRH, gonadotropin-releasing hormone, Factrel, LutrepulseNNC 26-0161, Ipamorelin acetate
EvidenceResearch-stageInvestigational (in trials)
Dosing range50mcg–200mcg mcg, 2–3x per week subcutaneous100mcg–300mcg mcg, 1–3x daily (typically pre-sleep and/or pre-workout)
AdministrationSubcutaneous injection, Intranasal (pulsatile delivery)Subcutaneous injection, Intramuscular injection
Key side effectsInjection site reactions, Headache, Nausea, FlushingWater retention (mild), Tingling / numbness in extremities, Increased appetite, Headache (transient)
Cited sources2 references3 references

Key differences

  • Evidence level differs: Gonadorelin is research-stage, while Ipamorelin is investigational (in trials).
  • Administration: Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery); Ipamorelin — Subcutaneous injection, Intramuscular injection.
  • Frequency: Gonadorelin is typically 2–3x per week subcutaneous; Ipamorelin is 1–3x daily (typically pre-sleep and/or pre-workout).
  • Research depth: this profile cites 2 sources for Gonadorelin vs 3 for Ipamorelin.

How each works

Gonadorelin

Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.

Ipamorelin

Ipamorelin selectively stimulates GH release via the ghrelin receptor (GHS-R1a) without significantly elevating ACTH or cortisol — the feature that distinguishes it from GHRP-6 and GHRP-2 (Raun et al., 1998, in swine/rodent models). Human data are limited: a PK study in 40 volunteers established a ~2-hour half-life (Gobburu et al., 1999), and a Phase 2 trial for postoperative ileus (Beck et al., 2014) failed its primary endpoint. It is not FDA-approved, and claims about body composition or recovery are extrapolated from GH physiology, not human outcome trials.

Read the full Gonadorelin profileRead the full Ipamorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.